Investigation of the Effects of Flunixine Meglumine and Meloxycam Administration on Coagulation Profiles in Healthy Sheeps

Abstract

In this study, it was aimed to investigate the effects of flunixin meglumine and meloxicam application on coagulation

profile in healthy sheep. Animals with physical examination findings and hemogram and biochemical data within physiological

limits were included in the study and randomly distributed among the groups. Healthy sheep were divided into two groups,

Group 1 (n=7) and Group 2 (n=7). In this study, groups 1 and 2 were given intramuscular injections of flunixin meglumin at a

dose of 2.2 mg/kg/day and subcutaneous injections of 0.5 mg/kg/day of meloxicam for the first 3 days. 0 hours, 3 hours, 6

hours, 12 hours, 24 hours from vena jugularis to determine the platelet count [prothrombin time (PT), activated

thromboplastin time (APTT), fibrinogen (FIB) concentration] and platelet (PLT) count of coagulation profiles of animals in both

groups on day 1, day 2, day 3, day 6, day 12 and day 24 blood samples were taken with sodium citrate and 2 μl of

ethylenediamine tetraacetic acid (EDTA). NSAIDs were found to have a significant decreases in FIB concentrations and PLT

counts, prolonged PT levels in sheep treated with flunixine and meloxicam. There was no statistically significant difference in

hemostatic changes between the groups. In conclusion, it was concluded from the NSAIDs that flunixin meglumin and

meloxicam treated sheep were carefully followed by conventional routine hemostatic changes of PLT, PT, FIB levels.

Keywords

• Coagulation profile,Flunixin meglumin,Meloxicam,Sheep

Sağlıklı Koyunlarda Fluniksin Meglumin ve Meloksikam Uygulamasının Koagulasyon Profili Üzerine Etkilerinin Araştırılması

Öz

Bu çalışmada, sağlıklı koyunlarda fluniksin meglumine ve meloksikam uygulamasının koagulasyon profili üzerine

etkilerinin araştırılması amaçlandı. Fiziksel muayene bulgularıyla birlikte hemogram ve biyokimyasal verileri fizyolojik sınırlar

içerisinde olan hayvanlar çalışma kapsamına alınıp gruplar içerisine rastgele dağıtıldı. Bu çalışmada, sağlıklı koyunlar Grup 1

(n=7) ve Grup 2 (n=7) olmak üzere iki guruba ayrıldı. Grup 1’ deki koyunlara fluniksin meglumin 2.2 mg/kg/gün dozunda

intramusküler, Grup 2’ deki hayvanlara da meloksikam 0.5 mg/kg/gün dozunda subkutan olarak ilk 3 gün boyunca uygulandı.

Her iki gruptaki hayvanların koagulasyon profillerinin [protrombin zamanı (PT), aktive edilmiş tromboplastin zamanı (APTT),

fibrinojen (FIB) konsantrasyonu] ve trombosit (PLT) sayımının belirlenebilmesi için vena jugularis’den 0. saat, 3. saat, 6. saat,

12. saat, 24. saat, 2. gün, 3. gün, 6. gün, 12. gün ve 24. günde kan örnekleri sodyum sitratlı ve etilendiamin tetraasetikasit

(EDTA)’ lı tüplere 2’ şer ml alındı. Non-steroid antienflamatuar ilaçlardan fluniksin meglumin ve meloksikam ile tedavi edilen

koyunlarda zamana bağlı olarak FIB ve PLT konsantrasyonlarında azalma, PT seviyelerinde ise uzamanın olduğu ve bu

değişikliklerin istatistiksel açıdan önemli olduğu belirlendi. Gruplar arasında hemostatik değişiklikler açısından istatistiksel

olarak belirgin bir farkın olmadığı belirlendi. Sonuç olarak NSAİİ’ lerden fluniksin meglumin ve meloksikam ile tedavi edilen

koyunlarda konvansiyonel rutin hemostatik değişikliklerden FIB, PLT, PT, düzeylerinin dikkatle takibi alınması kanısına varıldı.

Anahtar Kelimeler

• Fluniksin meglumin,Koagulasyon profili,Koyun,Meloksikam,Trombosit,Trombosit

Kaynakça

1. 1. Karol AM., 2002. Non-steroidal anti-inflammatory analgesics: a review of current practice. J Vet Emerg and Critic Care 12(2): 89-97.
2. 2. Langston C., 2004. USP veterinary pharmaceutical information monographs-antiinflammatories. J Vet Pharm Therap 27: 1-112.
3. 3. Curry SL., Cogar SM., Cook JL., 2005. Nonsteroidal antiinflammatory drugs: A review. J Am An Hos Assoc 41(5): 298-309.
4. 4. KuKanich, B., Bidgood, T., & Knesl, O., 2012. Clinical pharmacology of nonsteroidal anti‐inflammatory drugs in dogs. Vet Anaesth Analg, 39(1): 69-90.
5. 5. Brainard BM., Meredith CP., Callan MB., Budsberg SC., Shofer FS., Driessen B., & Otto, CM., 2007. Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs. Am J Vet Res., 68(3): 251-257.
6. 6. Luna SP., Basílio AC., Steagall PV., Machado LP., Moutinho FQ., Takahira RK., & Brandão CV., 2007. Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. Am J Vet Res., 68(3): 258-264
7. 7. Lascelles BDX., Mcfarland MJ., 2005. Guidelines for safe and effective use of NSAIDs in dogs, Vet Ther. 6(3): 1-15.
8. 8. Kaya S., 2006. Narkotik Olmayan Ağrı Kesiciler. Kaya S. Eds. In: Veteriner Farmakoloji. 4. Baskı. Ankara: Medisan Yayınevi, 295-320.

9. 9. Kopcha M., ve Ahl AS., 1989. Experimental use of flunixin meglumine and phenyl butazone in food producing animals. Am J Vet Res. 11, 479-491.
10. 10. Blois SL., Allen DG., Wood RD., Conlon PD.. 2010. Effects of aspirin, carprofen, deracoxib, and meloxicam on platelet function and systemic prostaglandin concentrations in healthy dogs. Am J Vet Res.71(3): 349-358.
11. 11. Fthenakis GC., 2000. Field evaluation of flunixin meglumine in the supportive treatment of ovine mastitis. J Vet Pharmacol Ther. 23(6):405-7.
12. 12. Zamir S., Rozov A., Gootwine E., 2009. Treatment of pregnancy toxaemia in sheep with flunixin meglumine. Vet Rec. 29; 165(9): 265-6.
13. 13. Gentry PA., 2004. Comparative aspects of blood coagulation. Vet J. 168:238–251
14. 14. Hickford FH., Barr SC., Erb HN., 2001. Effect of carprofen on hemostatic variables in dogs. Am J Vet Res.62(10): 1642-1646.
15. 15. Bulla C., Kiomi TR., Pessoa Jr., Aparecida TL., Souza LR., Wiedmeyer CE., 2004. The relationship between the degree of thrombocytopenia and infection with Ehrlichia canis in an endemic area, Vet Res. 35(1):141-6.
16. 16. Luba M., Gusarski I., 2005. Thrombocytopenia as a complication of nonsteroidal anti-inflammatory drug treatment, Przegl Lek. 62(12):1556-7.
17. 17. Herring J., and McMichael M., 2012. Diagnostic Approach to Small Animal Bleeding Disorders, Topics in Compan An Med. 27: 73-80.
18. 18. Zimmerman KL., 2000. Drug-induced thrombocytopenias. In: Feldman BF, Zinkl JG, Jain NC, eds. Schalm’s veterinary hematology. 5th ed. Philadelphia: The Williams & Wilkins Co, 472–477.
19. 19. Brooks M., Catalfamo J., 2005. Platelet disorders and von Willebrand disease. In: Ettinger SJ, Feldman EC, eds. Textbook of veterinary internal medicine. 6th ed. St Louis: WB Saunders Co, 1918–1929.
20. 20. Schafer AI., 1995. Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function and Systemic Hemostasis J Clin Pharmacol. 35(3):209-19.
21. 21. Foley S., 2014. A comprehensive study of ovine haemostasis to assess suitability to model human coagulation. Thromb Res. 134(2), 468-473.
22. 22. Wilhelmi MH., Tiede A., Teebken OE., Bisdas T., Haverich A., & Mischke R., 2012. Ovine blood: establishment of a list of reference values relevant for blood coagulation in sheep. ASAIO Journal. 58(1): 79-82.
23. 23. Gajewski J, Povar ML., 1971. Blood coagulation values of sheep. Am J Vet Res. 32, 405-409.
24. 24. Tligui N, Ruth GR. 1994. Ferula communis variety brevifolia intoxication of sheep. Am J Vet Res. 55(11):1558–63.
25. 25. Osbaldiston GW., Hoffman MW., 1971. Blood coagulation valves in normal sheep and in two mutant strains with hyperbilirubinemia. Can J Comp Med 35(2):150–4
26. 26. Webb JA., Allen DG., Abrams-Ogg AC., Gentry PA., 2006. Effects of doxycycline, amoxicillin, cephalexin, and enrofloxacin on hemostasis in healthy dogs. Am J Vet Res. 67(4):569-76.
27. 27. Everse SJ., Spraggon G., Veerapandian L., Riley M., Doolittle RF., 1998. Crystal structure of fragment double-D from human fibrin with two different bound ligands. Biochemistry 37(24): 8637–8642.
28. 28. Hajsadeghi S., Kerman SR., Khojandi M., Vaferi H., Ramezani R., Jourshari NM., Mousavi SA., Pouraliakbar H., 2012. Accuracy of D-dimer: fibrinogen ratio to diagnose pulmonary thromboembolism in patients admitted to intensive care units. Cardiovasc J Afr. 23(8):446-56.